Domainex, a privately-owned drug discovery services company, is pleased to announce that Chris Brown has been appointed Chief Financial Officer with immediate effect.
Brown will have a pivotal role in supporting the organisation through ongoing and significant growth and investment; his appointment will strengthen both the existing board and executive management team.
Domainex is expanding rapidly, with compounded annual growth in revenue of more than 30% per annum during the past five years and an increase in its international team of scientists at the company’s research facilities on the Chesterford Research Park near Cambridge UK, by more than 50% in the past 12 months.
“I am thrilled to join Domainex at this exciting stage of the company’s development,” said Brown.
“Domainex enjoys an outstanding reputation for scientific excellence in drug discovery. I believe we are in a strong position to build on our capabilities to serve our global client base. I look forward to developing and implementing our future growth strategies in drug discovery services.”
Chris Brown is a mathematics graduate of Imperial College and a Chartered Accountant. He has extensive experience within the life sciences industry with more than 10 years at Envigo where he rose to become Senior VP of Finance.
Chris Brown brings a strong financial technical skill set to the company and experience in M&A transactions having previously acted as the financial lead on the acquisition of Harlan Laboratories, a 2000 person global scientific models and CRO business, to create Envigo.
“We are delighted to welcome Chris to the team,” said Dr Timo Veromaa, Executive Chairman of the company.
“We are exploring a number of exciting growth opportunities for Domainex and feel Chris’ expertise will be of tremendous value in this area. I would also like to thank Barry Knight for his excellent service as our part-time CFO and wish him well in his future endeavours.”